Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAD Study of M1 PAM VU0467319 in Healthy Volunteers
NCT04051801Phase 1Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- May 2021
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VU0467319 in Alzheimer's disease (AD) (6 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Safety and Tolerability. Planned start May 2021; status: withdrawn.
02
Drugs
VU0467319
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04051801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04051801.